Abstracts tagged "quality of life"

Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Vibeke Strand¹, Philip Mease², Enrique Soriano³, Mitsumasa Kishimoto⁴, Carlo Salvarani⁵, Nemanja Damjanov⁶, Jaclyn K Anderson⁷, Erin Blondell⁷, Patrick Zueger⁷, Christopher Saffore⁷ and Dafna Gladman⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁵Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷AbbVie Inc., North Chicago, IL, ⁸Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
Abstract Number: 0198 • ACR Convergence 2020
A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis
Kaleb Michaud¹, Jennifer Merickel¹, Yeongjin Gwon¹, Harlan Sayles¹, Haley Kampschnieder¹, Rebecca Hiebert¹, Alison Petro¹, Bryant England¹, Matthew Rizzo¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an instrumental activity of daily living. Owing to symptoms and functional impairment, patients with rheumatoid arthritis (RA) rely disproportionately on driving…
Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Frank Behrens¹, Ulrich Prothmann², Thilo Klopsch³, Ann-Dörthe Holst⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Saarland, Germany, ³Rheumatological Practice, Neubrandenburg, Mecklenburg-Vorpommern, Germany, ⁴Specialist Practice for General Medicine incl. Rheumatology and Acupuncture, Ludwigslust, Mecklenburg-Vorpommern, Germany, ⁵Pfizer Pharma GmbH, Berlin, Berlin, Germany
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…
Abstract Number: 1371 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs
Vibeke Strand¹, Filip Van den Bosch², Roberto Ranza³, Ying Ying Leung⁴, Edit Drescher⁵, Apinya Lertratanakul⁶, Ralph Lippe⁷, Christopher Saffore⁶, Patrick Zueger⁶ and Peter Nash⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Ghent University Hospital, Ghent, Belgium, ³Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…
Abstract Number: 0249 • ACR Convergence 2020
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Chi Chiu Mok¹, Ling Yin Ho¹, Kar Li Chan² and Meenakshi Jolly³, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Rush University, Chicago, IL
Background/Purpose: The SIMPLE (SIMple Disease Assessment for People with Lupus Erythematosus) index is a composite numeric tool that captures disease activity from patients’ self-assessment with…
Abstract Number: 1020 • ACR Convergence 2020
Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Cutaneous Lupus Erythematosus
Cristina Drenkard¹, Laura Aspey¹, Gaobin Bao¹, Caroline Gordon², Kristina Theis³, Charles Helmick³ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²University of Birmingham, Birmingham, England, United Kingdom, ³Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Chronic stress may trigger or exacerbate physiologic pathways that worsen individual health and wellbeing. Stress is associated with the development and progression of skin…
Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Smriti Prasad¹, Samantha Black², Shivani Sharma³ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Shilpa Arora¹, Patricia Katz², Jinoos Yazdany³, Joel Block¹, Edward Yelin⁴ and Meenakshi Jolly⁵, ¹Rush University Medical Center, Chicago, IL, ²University of California, San Francisco, Novato, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Rush University, Chicago, IL
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…
Abstract Number: 1072 • ACR Convergence 2020
Sexual Health Impairment in 62 Female Patients with Idiopathic Inflammatory Myopathies
Barbora Hermankova¹, Maja Spiritovic², Sabina Oreska³, Hana Storkanova⁴, Hana Smucrova⁵, Martin Komarc⁶, Martin Klein⁴, Karel Pavelka⁷, Ladislav Šenolt⁷, Jiří Vencovský⁷, Heřman Mann⁴ and Michal Tomcik⁴, ¹Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Hlavni mesto Praha, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare diseases characterized by chronic muscle inflammation and multiple organ involvement. These serious clinical manifestations…
Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Ales Janda⁶, Tilmann Kallinich⁷, Prasad T. Oommen⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Norbert Blank¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, ⁷Charite, Berlin, Germany, ⁸Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
Abstract Number: 059 • 2020 Pediatric Rheumatology Symposium
Challenges Faced by Families of Children with an Auto-inflammatory Disease
Lori Tucker¹, Maria Belen ², Jenny Tekano ², Iwona Niemietz ³, Martina Sundqvist ³ and Kelly Brown ³, ¹BC Children's Hospital, Vancouver, British Columbia, Canada, ²BC CHildren's Hospital, Vancouver, Canada, ³BC Children's Hospital Research Institute, Vancouver, Canada
Background/Purpose: Auto-inflammatory diseases (AIDs) are rare disorders that usually present in young children. Disease episodes, characterized by recurrent inflammation, are often frequent and unpredictable, and…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
Abstract Number: 104 • 2020 Pediatric Rheumatology Symposium
Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life
Mariana Correia Marques¹, Nicole Tennermann ², Sivia Lapidus ³, Grant Schulert ⁴, Jennifer Tousseau ², Rashmi Sinha ⁵, Karen Durrant ⁶, Saskya Angevare ⁷ and Fatma Dedeoglu ⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ², ³The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, ⁴Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, ⁵Systemic JIA Foundation, Cincinnati, ⁶Autoinflammatory Alliance, San Francisco, ⁷Amersfoort, Netherlands, ⁸Boston Children's Hospital, Boston
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) encompass multiple clinical entities in which spontaneous inflammation occurs due to dysregulation of the innate immune response. The variability in…
Abstract Number: 117 • 2020 Pediatric Rheumatology Symposium
Family Impact of Juvenile Localized Scleroderma
Katia Milovanova¹, Vimal Prajapati ², Merna Adly ², Rebeka Stevenson ³, Brendan Lethebe ² and Nadia Luca ², ¹University of Alberta, Edmonton, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Cochrane, Alberta, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare autoimmune disease that can lead to significant morbidity. Previous studies have focused on predictors of patient health-related…
Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Sofia Soukka ¹, Alvaro Gomez ¹, Yvonne Enman ¹, Petter Johansson ¹, Sharzad Emamikia ¹ and Katerina Chatzidionysiou ¹, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].